Spyre Therapeutics raises ~$316M in public offering of 17M shares at $18.50

Spyre Therapeutics, Inc.

Sold 14,864,865 shares at $18.50; underwriters exercised option for 2,229,729 additional shares.
Gross proceeds of approximately $316.2 million before underwriting discounts and expenses.
Net proceeds to fund IBD and rheumatic disease programs, including clinical trials and Phase 3 readiness.
Underwriters include Jefferies, TD Securities, Leerink Partners, and Stifel; offering closed Oct 15, 2025.
Offering was made under existing effective shelf registration statement (File No. 333-285341).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.